Please login to the form below

Not currently logged in
Email:
Password:

Takeda offloads select portfolio to Acino ahead of Shire takeover

Hopes to reduce debt before acquistion completion

Takeda

Japanese pharma Takeda has agreed to divest a number of over-the-counter (OTC) and prescription medicines in emerging markets to Acino for $200m. 

These markets comprise Near East, Middle East and Africa (NEMEA) countries, which are all within Takeda’s Growth and Emerging Markets Business Unit.

Takeda is set to sell approximately 30 of its pharmaceutical assets to the Swiss pharma, which has a clear focus on selected markets in the Middle East, Africa, the CIS Region and Latin America.

Acino will acquire the rights, title and interest to the products included in the agreed portfolio, exclusive to the selected countries. The transaction is expected to close by the fourth quarter of 2019, and is subject to the satisfaction of closing conditions from Takeda.

“Takeda remains committed to this region, as we continue our work in accelerating access to our life-changing portfolio of innovative products to meet the needs of patients. We will do this via our commercial activities and Takeda’s Access to Medicines programme,” said Ricardo Marek, President, Growth and Emerging Markets Business Unit, Takeda.

"We are confident that Acino is best positioned to provide uninterrupted access and supply of the divested products to patients,” he added.

According to the company, while these products are outside of Takeda’s primary business areas, which are gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience.

“The divestment of non-core assets sold in NEMEA represents the continued execution of our strategy to optimise our portfolio, invest in the defined core business areas, and accelerate our progress toward reaching our target leverage ratio,” said Costa Saroukos, chief financial officer, Takeda.

According to a statement from Takeda, it will use the cash from the deal to reduce its debts, following its takeover of Shire. The acquisition was initially met with some resistance from rebel shareholders, as the takeover will accrue a massive amount of debt – around $30bn.

However, Takeda maintained that Shire will help it grow outside Japan, and increase the company’s pipeline in the process. Takeda has already made a few sacrifices to fund the deal, including the sale of its Osaka headquarters.

This deal with Acino is unlikely to be the last for Takeda, as it continues to raise funds to counteract its debts. The takeover, if all goes smoothly, is expected to close on 8 January next year.

Article by
Lucy Parsons

17th October 2019

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Infographics